For decades, the gold standard for measuring bone health is the DXA scan, which estimates bone mineral density to assess osteoporosis and fracture risk. While effective, DXA has limitations — it cannot separate the inner, spongy trabecular bone from the dense outer cortical bone, and monitoring meaningful changes, often take years to detect. Enter REMS (Radiofrequency Echographic Multi-Spectrometry), a breakthrough ultrasound technology that is transforming how we monitor and manage bone health.
Unlike traditional X-ray-based scans, REMS is radiation-free, making it safer for repeated use. This means patients can check their progress more frequently, tracking the impact of lifestyle changes, supplementation, or therapy without added risk. Where DXA may require two or more years to detect statistically significant changes in bone density, REMS’s precision allows reassessment in as little as 8 to 12 months. This shorter window gives patients and clinicians earlier insight into whether interventions are working or need adjustment — a crucial advantage for those actively working to strengthen bones.
One of REMS’s most innovative features is the Fragility Score, a 0-to-100 index that goes beyond simple mineral density. By analyzing the ultrasound signal, REMS evaluates not only how much bone is present, but also the quality and structural integrity of the bone. It accounts for cortical thickness, trabecular connectivity, and bone stiffness, providing a functional measure of fracture risk. This approach offers a more complete picture than traditional DXA scans, which report only a single composite BMD value. For patients who may appear borderline or normal on DXA, the Fragility Score can reveal hidden weakness, guiding early intervention.
REMS also distinguishes between cortical and trabecular bone, offering insight into two critical compartments of the skeleton. Cortical bone forms the dense outer shell, providing structural strength, while trabecular bone — the spongy interior — is highly metabolic and responds quickly to therapy or lifestyle changes. Monitoring both compartments separately allows clinicians to detect subtle improvements or losses that might be missed with traditional scans. The technology has gained attention beyond the clinic. Even NASA has explored REMS for monitoring astronauts’ bones in space, where rapid bone loss is a major concern.
In practical terms, REMS offers patients a more responsive, individualized approach to bone care. Those incorporating calcium and vitamin D supplementation, vitamin K, collagen protein, or weight-bearing exercise, can see early evidence of benefit in under a year. Clinicians, in turn, can adjust therapy sooner, improving outcomes and potentially reducing fracture risk.
As awareness grows, REMS is poised to complement — and in some cases, enhance — traditional bone health monitoring. For anyone concerned about osteoporosis, fragile bones, or early intervention, REMS represents a powerful, precise, and patient-friendly tool for keeping bones strong and resilient. Watch out for next month’s article on Bone Builder supplements. Our next Bone Health Screening clinic is on Mar 9th.
Register HERE
Lyle Sunada is a compounding pharmacist and NAMS Certified Menopause Practitioner specializing in hormone balancing and alternative medicine at Cloverdale Pharmasave. Everything mentioned in the article is available In-Store.
